H Plus Yangji Hospital
Seoul, South Korea
Location status: Recruiting
NCT Number: NCT06884098
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.
Interested in participating?
Request Info19 year and older
All sexes
Interventional
Phase 1
Seoul, South Korea
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
AD-228B, 1Tab., Per Oral
AD-2284, 1Tab., Per Oral
Time frame: pre-dose (0hour) to 72hours
Cmax of AD-228B
Time frame: pre-dose (0hour) to 72hours
AUCt of AD-228B
Contact information is provided by the study sponsor or research team.
Addpharma Inc.
Industry
An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-228B with AD-2284 in Healthy Adult Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07206472
Mixed Dyslipidemia, Primary Hypercholesterolaemia
São Paulo, Brazil
View Trial DetailsNCT06858865
Primary Hypercholesterolaemia
Seoul, South Korea
View Trial DetailsNCT06646354
Cardiovascular Diseases, Hypertension
Seoul, South Korea
View Trial DetailsNCT00269204
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
View Trial Details